Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus after hepatic arterial embolization for metastatic GEP-NEN
jRCT1061210015Completed
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of everolimus in gastroenteropancreatic neuroendocrine tumor (GEP-NET). Primary endpoint: Progression-Free Survival. Started Jul 2021; status: completed.
02
Drugs
everolimus
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on jRCT1061210015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061210015.